Cargando…
Development of a mechanism of action-reflective, dual target cell-based reporter bioassay for a bispecific monoclonal antibody targeting human CTLA-4 and PD-1
T-cell-mediated immunotherapy has generated much excitement after the success of therapeutic biologics targeting immune checkpoint molecules. Bispecific antibodies (BsAbs) that recognize two antigen targets are a fast-growing class of biologics offering promising clinical benefits for cancer immunot...
Autores principales: | Chen, Weimin, Pandey, Madhu, Sun, Hong, Rolong, Andrea, Cao, Mingyan, Liu, Dengfeng, Wang, Jihong, Zeng, Lingmin, Hunter, Alan, Lin, Shihua |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8078673/ https://www.ncbi.nlm.nih.gov/pubmed/33870864 http://dx.doi.org/10.1080/19420862.2021.1914359 |
Ejemplares similares
-
Simultaneous Inhibition of PD-1 and Stimulation of CD40 Signaling Pathways by Anti-PD-L1/CD40L Bispecific Fusion Protein Synergistically Activate Target and Effector Cells
por: Pandey, Madhu S., et al.
Publicado: (2021) -
Characterization and analysis of scFv-IgG bispecific antibody size variants
por: Cao, Mingyan, et al.
Publicado: (2018) -
Cadonilimab, a tetravalent PD-1/CTLA-4 bispecific antibody with trans-binding and enhanced target binding avidity
por: Pang, Xinghua, et al.
Publicado: (2023) -
Bispecific antibodies targeting CTLA-4: game-changer troopers in cancer immunotherapy
por: Farhangnia, Pooya, et al.
Publicado: (2023) -
A systematic approach for analysis and characterization of mispairing in bispecific antibodies with asymmetric architecture
por: Wang, Chunlei, et al.
Publicado: (2018)